ZTS Price Prediction Next Week
Technical Analysis
Based on the latest market data, ZTS closed at $168.61 on January 24, 2025, with a regular market gain of 0.99%. The stock is currently showing mixed technical signals.
The RSI(14) reading of 51.88 indicates a neutral momentum, suggesting the stock is neither overbought nor oversold. The stock is trading below its 200-day SMA of $175.63 but above its 20-day SMA of $165.33, indicating a potential consolidation phase.
News Impact
Recent significant news that could impact next week's trading:
European and U.S. regulators are investigating potential health concerns regarding ZTS's arthritis medications for animals. This regulatory scrutiny could create near-term pressure on the stock.
Piper Sandler's recent survey highlights ZTS as the only overweight-rated stock in the animal health sector, noting its strong pricing power and irreplaceable therapeutics despite macro challenges.
Price Prediction for Next Week
Based on Fibonacci levels:
- Resistance levels: R1: $169.13, R2: $171.06, R3: $174.19
- Support levels: S1: $162.86, S2: $160.93, S3: $157.79
- Pivot: $165.99
Expected price movement:
- Base case (60% probability): Range-bound trading between $162-$169
- Bearish case (30% probability): Drop to $160-$162 if regulatory concerns escalate
- Bullish case (10% probability): Break above $171 if market sentiment improves
Trading Recommendation
SELL with target entry at current levels ($168-$169):
- Initial target: $162.86 (S1)
- Stop loss: $171.06 (R2)
Rationale:
- Regulatory investigation creates significant near-term risk
- Trading below 200-day SMA indicates bearish long-term trend
- Animal health sector facing headwinds until late 2025
- Current price near resistance level provides favorable risk-reward for short positions
ZTS Similar Chart Price Prediction
The price of ZTS is predicted to go up -32.54%, based on the high correlation periods with GRI. The similarity of these two price pattern on the periods is 97.73%.
ZTS
GRI
Down: -32.54%Similarity: 97.73%
ZTS Revenue Forecast
ZTS EPS Forecast
ZTS FAQs
What is revenue forecast for next quarter？
What is eps forecast for next quarter？
ZTS VS S&P500
Growing interest in probiotics, antibacterial peptides, and immune modulators as alternatives to antibiotics offer many targets for innovation.
Companion animals are increasingly viewed as family members, drastically increasing owners' willingness to spend on pet healthcare.
Because the animal health industry lacks large payers like Medicare, single-payer governments, or large insurance companies, Zoetis maintains significant pricing power.
ZTS Analyst's Forecast
Daniel Clark
Leerink Partners
Buy
Price Target
$215
Upside
+21.6%
Leerink analyst Daniel Clark initiated coverage of Zoetis with an Outperform rating and $215 price target. The firm notes . Zoetis has been one of the best performing names in animal health from a growth perspective, with a core competency of identifying new market opportunities and successfully executing against them. This has led to the company growing its top line and EPS at a rate above the broader space. Looking ahead, Leerink forecasts more above industry growth for Zoetis, with its assumptions supported by findings of a proprietary MEDACorp survey of 53 veterinarians.
Jonathan Block
Stifel
Strong Buy
Price Target
$200 → $210
Upside
+6.9%